FDA Approves the First Gene Therapy to Treat an Inherited Disease

by Patterson Belknap Webb & Tyler LLP

On December 19, 2017, FDA approved the gene therapy Luxturna (voretigene neparvovec-rzyl), developed by Spark Therapeutics, to treat children and adults with biallelic REP65 mutation-associated retinal dystrophy, an inherited disease of the eye.  Luxturna is the United States’ first approved gene therapy for treatment of an inherited disease, and its approval comes ahead of the January 2018 target date set by FDA when it granted Priority Review for Spark Therapeutics’ Biologics License Application in July 2017.  The agency’s announcement also follows FDA’s approval of two other gene therapy products earlier this year, each to treat a certain form of cancer:  Novartis’ Kymriah (tisagenlecleucel), approved on August 30, 2017, and Gilead Sciences’ Yescarta (axicabtagene ciloleucel), approved on October 18, 2017.  Gene therapy has arrived, and FDA is regulating these products as biologics, giving them twelve-year non-patent exclusivity. 

Luxturna targets retinal dystrophy that is caused by a defective RPE65 gene.  Normally, the REP65 gene encodes an enzyme, located in retinal cells, that facilitates the process by which light is transformed into the electrical signals that transmit to the brain and enable a person to see.  Persons born with a faulty RPE65 lack that enzyme and, over time, experience vision loss which may lead to total blindness.

A physician administering Luxturna injects a solution containing billions of viruses filled with functioning RPE65 genes into a patient’s retina; once in the eye, the virus transports the curative DNA to retinal cells which then begin producing the crucial enzyme.  Clinical trials showed that gradually, following treatment, patients’ vision was significantly improved. 

Luxturna differs from Kymriah (developed to treat a form of pediatric leukemia) and Yescarta (developed to treat a form of lymphoma), both of which are CAR T-cell based gene therapies.   CAR T-cell therapy does not involve injecting DNA directly into a patient.  Rather, white blood cells called T-cells are collected from the patient’s body and then modified with a protein-encoding gene.  The protein causes the cell to find and kill cancer cells that have a certain kind of antigen on their surface (“CAR” stands for “chimeric antigen receptor”).  The modified white blood cells are reintroduced into the patient, where they get to work attacking cancerous cells.

Regardless of the mechanism used, however, these newly approved treatments represent innovative milestones.  Gene therapy offers exciting possibilities but it is also expensive.  Some analysts expect Luxturna to carry a $1 million price tag, although Kymriah and Yescarta have marketed their treatments for $475,000 and $373,000, respectively—lower than analysts originally predicted.

Gene therapy developers are surely relying on the non-patent exclusivity afforded to them by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”).  The BPCIA amended the Public Health Service Act (“PHSA”) to grant biologic innovators exclusivity for a twelve-year period before competing biosimilars can be marketed.  42 U.S.C. § 262(k)(7)(A).  FDA has regulated gene therapies like other biologic products, includes gene therapy in its own definition of “biologics,” and has already listed Yescarta and Kymriah in the so-called Purple Book, FDA’s compilation of products it has licensed under the PHSA. 

The PHSA does not explicitly list gene therapy as a biologic product.  It defines “biological product” as any “virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.”  42 U.S.C. § 262(i)(1).  The scope of this definition has not been subject to much litigation.  One case that has addressed the definition, however, shows that it may be construed broadly.  In United States v. Regenerative Sciences, LLC, Regenerative Sciences challenged an FDA enforcement action against it related to a stem cell treatment it had developed and administered, arguing that the treatment was neither a drug nor biologic and thus not subject to FDA regulation.  878 F. Supp. 2d 248, 251-52 (D.D.C. 2012).  The court agreed with FDA that the treatment constituted a biologic under the PHSA because the treatment’s curative stem cells were “derived from a patient’s bone marrow” and thus constituted a “blood, blood component or derivative, . . . or analogous product.”  Id. at 257.

According to Regenerative Sciences and the statute’s text, the newly approved gene therapies also are likely to meet the statutory definition of biologics:  Kymriah and Yescarta involve the manipulation of cells removed from and reinserted into a person’s blood, and Luxturna relies on a virus to serve as a DNA transporter.  FDA is regulating these products as biologics and courts are likely to agree with its interpretation.  But for these and other gene therapies, it is the genetic material that “prevent[s], treat[s], or cure[s]” the targeted disease.  And genetic material—central to FDA’s definition of “gene therapy,” see 66 Fed. Reg. 4688 (Jan. 18, 2001) and the quintessential biologic product—is absent from the PHSA’s enumeration of biologic products.  Though FDA’s interpretation is likely to prevail, it is possible that some companies may challenge it.

The BPCIA’s twelve years of non-patent exclusivity is undoubtedly important to the burgeoning gene therapy industry.  Certain innovators may be choosing to develop gene therapies relying on the protections of the BPCIA and FDA’s regulation of gene therapy as a biologic.  Biosimilar makers also are likely to embrace FDA’s regulation of gene therapy as a biologic product since it permits them to obtain approval of gene therapy products using an abbreviated regulatory pathway.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP

Patterson Belknap Webb & Tyler LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.